An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro (IC51) in an Elderly Population.
Phase of Trial: Phase IV
Latest Information Update: 23 Jul 2016
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions
- Sponsors Valneva
- 22 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 13 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.